Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from ...

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

A woman got routine bloodwork during her second pregnancy and was shocked when the test results came back: It suggested her ...

IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer.

Taking to X, Moss shared a new website that he's created - RandyMoss.com - which will serve as a pancreatic cancer awareness ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of ...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol ...

The rates of life-threatening breast cancer are spiking among women of all ages, with a significant increase in those under 40. A new study found that cases of metastatic breast cancer — in which ...

Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient ...